These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
546 related articles for article (PubMed ID: 31574376)
1. Inhibition of autophagy enhances the anticancer effect of enzalutamide on bladder cancer. Quan Y; Lei H; Wahafu W; Liu Y; Ping H; Zhang X Biomed Pharmacother; 2019 Dec; 120():109490. PubMed ID: 31574376 [TBL] [Abstract][Full Text] [Related]
2. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth. Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033 [TBL] [Abstract][Full Text] [Related]
3. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells. Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525 [TBL] [Abstract][Full Text] [Related]
4. Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells. Kang M; Lee KH; Lee HS; Jeong CW; Kwak C; Kim HH; Ku JH Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28165387 [TBL] [Abstract][Full Text] [Related]
5. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder. Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613 [TBL] [Abstract][Full Text] [Related]
6. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401 [TBL] [Abstract][Full Text] [Related]
8. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012 [TBL] [Abstract][Full Text] [Related]
9. Autophagy induction enhances tetrandrine-induced apoptosis via the AMPK/mTOR pathway in human bladder cancer cells. Kou B; Liu W; Xu X; Yang Y; Yi Q; Guo F; Li J; Zhou J; Kou Q Oncol Rep; 2017 Nov; 38(5):3137-3143. PubMed ID: 29048631 [TBL] [Abstract][Full Text] [Related]
10. Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells. Lin JF; Lin YC; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI Drug Des Devel Ther; 2016; 10():1501-13. PubMed ID: 27143856 [TBL] [Abstract][Full Text] [Related]
11. BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1/AMPK in bladder cancer cells. Li F; Yang C; Zhang HB; Ma J; Jia J; Tang X; Zeng J; Chong T; Wang X; He D; Guo P Cancer Med; 2019 Aug; 8(10):4792-4805. PubMed ID: 31250978 [TBL] [Abstract][Full Text] [Related]
12. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth. Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407 [TBL] [Abstract][Full Text] [Related]
13. Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression. Chen J; Li L; Yang Z; Luo J; Yeh S; Chang C Cancer Lett; 2017 Nov; 408():155-163. PubMed ID: 28826721 [TBL] [Abstract][Full Text] [Related]
14. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer. Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035 [TBL] [Abstract][Full Text] [Related]
15. Enzalutamide inhibits proliferation of gemcitabine-resistant bladder cancer cells with increased androgen receptor expression. Kameyama K; Horie K; Mizutani K; Kato T; Fujita Y; Kawakami K; Kojima T; Miyazaki T; Deguchi T; Ito M Int J Oncol; 2017 Jan; 50(1):75-84. PubMed ID: 27909718 [TBL] [Abstract][Full Text] [Related]
16. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L. Wang R; Lin W; Lin C; Li L; Sun Y; Chang C Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475 [TBL] [Abstract][Full Text] [Related]
17. Chloroquine Enhances the Radiosensitivity of Bladder Cancer Cells by Inhibiting Autophagy and Activating Apoptosis. Wang F; Tang J; Li P; Si S; Yu H; Yang X; Tao J; Lv Q; Gu M; Yang H; Wang Z Cell Physiol Biochem; 2018; 45(1):54-66. PubMed ID: 29316551 [TBL] [Abstract][Full Text] [Related]
18. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer. Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075 [TBL] [Abstract][Full Text] [Related]
19. Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells. Lin JF; Lin YC; Tsai TF; Chen HE; Chou KY; Hwang TI Drug Des Devel Ther; 2017; 11():1517-1533. PubMed ID: 28553083 [TBL] [Abstract][Full Text] [Related]
20. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer. Thaper D; Vahid S; Kaur R; Kumar S; Nouruzi S; Bishop JL; Johansson M; Zoubeidi A Sci Rep; 2018 Nov; 8(1):17307. PubMed ID: 30470788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]